AGP Executive Report
Last update: 9 hours agoBig Pharma Deal: Bristol Myers Squibb and China’s Hengrui Pharma just signed a global collaboration worth up to US$15.2 billion, covering 13 early-stage oncology, hematology, and immunology programs; BMS pays US$600M upfront plus milestone payments, with the deal expected to close in Q3 2026. Local Health Alert: Macau reported a new Legionnaires’ disease case—an 83-year-old man in serious condition after pneumonia and ICU treatment—bringing this year’s total to six. Mosquito Watch: The Health Bureau warned Macau’s mosquito breeding index jumped in April, raising dengue and chikungunya risk. Macau Mobility: Bus ridership hit a seven-year high in Q1, averaging 673,400 trips per day as visitor numbers stay strong. Gaming & Diversification: At G2E Asia, casino executives highlighted Macau’s push toward more suites and continued non-gaming growth, while Galaxy and Sands reported steady momentum.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
![<![CDATA[Bristol Myers Squibb, Hengrui Pharma Form $15.2 Billion Strategic Drug Development Collaboration]]>](https://cdn.sanity.io/images/0vv8moc6/pharmexec/92b02a7f6e0c466c155a40ec32a74d94a075d09b-1280x720.jpg)
